Item 7.01 Regulation FD Disclosure On May 29, 2026, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced new data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting further reinforcing the differentiated cardiac safety profile of its lead drug candidate, Annamycin (also known as “L-Annamycin” or “naxtarubicin”). A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
MBRX Moleculin Biotech, Inc. - 8-K
Accession
0001437749-26-0188197.019.01
Item 7.01 - Regulation FD Disclosure
144 words
Item 9.01 - Financial Statements and Exhibits
29 words
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated May 29, 2026 104 Cover page Interactive Data File (formatted as Inline XBRL document)